New pages
Jump to navigation
Jump to search
13 February 2025
- 02:4702:47, 13 February 2025 Inavolisib (hist | edit) [24,016 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Inavolisib |aOrAn=a |drugClass=phosphoinositide 3-kinase inhibitors |indicationType=treatment |indication=Inavolisib is a phosphoinositide 3-kinase inhibitor that is FDA approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer Breast cancer,...")
12 February 2025
- 10:5610:56, 12 February 2025 Zenocutuzumab-zbco (hist | edit) [7,445 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=HER2-and HER3-directed antibody |indicationType=treatment |indication=It is a bispecific HER2-and HER3-directed antibody indicated for the treatment of: • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.* • Adults with advanced, unresectable or metastatic pancreatic adenocarc...")
- 10:2010:20, 12 February 2025 Cosibelimab-ipdl (hist | edit) [6,051 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,...")
- 09:5609:56, 12 February 2025 Ensartinib (hist | edit) [6,265 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=Kinase inhibitor |indicationType=treatment |indication=It is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. |adverseReactions=Most common adverse reactions (incidence≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nause...")
8 February 2025
- 22:5722:57, 8 February 2025 Entrectinib (hist | edit) [5,425 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Entrectinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. And also adult and pediatric patients 12 years of age and older with solid tumors. |adverseReactions=Fatigue, Constipation, Dysgeusia (altered taste), Edema, Dizziness, Diarrhea, Nausea, Dysesthesia (abnorma...")
31 January 2025
- 19:0319:03, 31 January 2025 Olezarsen (hist | edit) [3,816 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=an |drugClass=Oligonucleotide |indicationType=treatment |indication=It is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). |adverseReactions=1-Injection site reactions 2-Decreased platelet count 3-Arthralgia |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>''...")
30 January 2025
- 20:3320:33, 30 January 2025 Cefepime, enmetazobactam (hist | edit) [32,110 bytes] Mohammad Waqas Danish (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Mohammad Waqas Danish, MBBS |genericName=Cefepime and Enmetazobactam |aOrAn=an |drugClass=fourth generation cephalosporin with an extended spectrum Beta-Lactamase Inhibitor |indicationType=treatment |indication=complicated urinary tract infections, including p.yelonephritis |adverseReactions=increase in transaminases, increased bilirubin, headache, and phlebitis/infusion site reactions. |blackBoxWarningTitle='''<span style="color:#...")
- 17:1017:10, 30 January 2025 Concizumab (hist | edit) [6,985 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Concizumab in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported...")
29 January 2025
- 16:0616:06, 29 January 2025 Zelsuvmi (hist | edit) [4,231 bytes] Amir Ghabousian (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Amir Ghabousian |genericName=Berdazimer |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |fdaLIADAdult=== Indications == '''Molluscum contagiosum''' == Dosing == * Zelsuvmi comes in a carton with Tube A (berdazimer gel), Tube B (hydrogel), and a dosing guide. * Dispense an equal amount of gel ('...")
25 January 2025
- 09:0709:07, 25 January 2025 PrabotulinumtoxinA-xvfs (hist | edit) [25,128 bytes] Ali Othman (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |genericName=prabotulinumtoxinA-xvfs |aOrAn=a |drugClass=HUMAN PRESCRIPTION DRUG LABEL |indicationType=treatment |indication=JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients |hasBlackBoxWarning=Yes |adverseReactions=The following serious adve...")